A phase I study of Amrubicin (AMR) and Cyclophosphamide in patients with advanced solid organ malignancies
A Phase II Study of Biweekly Cisplatin (C) and Paclitaxel (P) in the Treatment of Metastatic Breast Cancer
Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M VAC) as First Line Chemotherapy in Metastatic Breast Cancer: A Phase II Trial
A phase II trial of perioperative CV301 vaccination in combination with nivolumab and systemic chemotherapy for resectable hepatic-limited metastatic colorectal cancer
A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer
Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC)
Phase I study of everolimus (RAD001) with Irinotecan (Iri) and Cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC)
A Phase II trial of Neoadjuvant Capecitabine plus Irinotecan Followed by Combined Modality Capecitabine and Radiation Therapy for Patients with Locally Advanced Rectal Cancer
A Phase II Trial of Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) (IFL), Celecoxib and Glutamine as First Line Therapy for Advanced Colorectal Cancer (CRC)
A Phase II Trial of Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) (IFL), Celecoxib and Glutamine as First Line Therapy for Advanced Colorectal Cancer
A Prospective Randomized Hoosier Oncology Trial of 5-Fluorouracil versus 5-Fluorouracil Plus Levamisole in the Treatment of Metastatic Colorectal Cancer
A Prospective Randomized Study of 5-Fluorouracil Alone or with Cisplatin in the Treatment of Metastatic Colorectal Cancer
Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination (HR) defective or loss of heterozygosity (LOH) high-metastatic esophageal/GEJ/proximal gastric adenocarcinoma
Pre-operative Cetuximab and Radiation (XRT) for Patients (pts) with Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas
A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC)
A phase II single arm multi-center trial evaluating the efficacy of pembrolizumab in the treatment of patients (pts) with incurable platinum refractory germ cell tumors (GCT)
Phase I trial of pegylated liposomal doxorubicin in combination with BIBF 1120 (nintedanib) in platinum-resistant ovarian cancer
A Phase II, Open-Label, Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Patients with Recurrent or Resistant Epithelial Ovarian Cancer
Clinical Activity of Imatinib Mesylate (Gleevec) In Combination with Docetaxel In Patients With Advanced, Platinum-Resistant Ovarian Cancer Or Primary Peritoneal Carcinomatosis
A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC)
A Phase II Trial of Ifosfamide in the Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
A Phase II Hoosier Oncology Group Trial of interferon Alpha-2b (IFN) added to Cisplatin (CDDP) and 5-Fluorouracil (FU) in Recurrent or Metastatic Head and Neck Cancer
Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC)
Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC)
1017 SLAMF7+ CD8+ exhausted T cell-specific gene signature is associated with resistance to PD1 blockade in renal cell
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC)
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC)
Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors
A Multicenter Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) As First-Line Chemotherapy for Metastatic Urothelial Carcinoma (UC)
A Phase II Study of ALIMTA in Patients with Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
A Phase II Study of Weekly Paclitaxel (P) and Gemcitabine (G) in Advanced Transitional Cell Carcinoma (TCC) of the Urothelium)
A Phase II Study of Weekly Paclitaxel and Gemcitabine in Advanced Transitional Cell Carcinoma (TCC) of the Bladder
Secondary brain metastases prevention after Isolated intracranial progression on trastuzumab/pertuzumab or T-DM1 in patients with advanced human epidermal growth factor receptor 2+ breast cancer with the addition of tucatinib (BRIDGET)
Phase I/II Study of Stereotactic Radiosurgery with Concurrent Olaparib Followed by Adjuvant Durvalumab and Physician’s Choice Systemic Therapy in Subjects with Breast Cancer Brain Metastases (SOLARA)
Randomized phase II trial of pembrolizumab/carboplatin vs. carboplatin alone for breast cancer with chest wall recurrence: TBCRC044
Circulating TP53 mutations in TNBC after neoadjuvant chemotherapy is associated with rapid disease recurrence: Correlative analysis from clinical trial BRE12-158
Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative breast cancer (TNBC): Preplanned correlative results from clinical trial BRE12-158
A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of BRE09-146
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer
Gene expression combined with gene set enrichment analysis to identify markers of vinorelbine efficacy in breast cancer patients
PARP inhibition after preoperative chemotherapy in patients with triple negative breast cancer (TNBC) or known BRCA1/2 mutations
Thymidilate synthase gene copy number as predictive marker of capecitabine efficacy in breast cancer patients
A Phase II Study of Lonafarnib (LF) in Patients with Locally Advanced and Metastatic Breast Cancer (MBC)
